Join our newsletter

Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM

APILAM informs you that the personal data that you provide to us by filling in this form will be treated by APILAM as responsible for this web. The purpose of the collection and processing of personal data that we request is to manage the registration of this subscription and send periodic bulletins with information and prospective offer of products or services.

Legitimation: Consent of the interested party

As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).

The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.

You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.

You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.

Last update March 5, 2022

Maternal Cardiopathy

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Most cardiac diseases on the mother when compensated by appropriate treatment are not a contraindication of breastfeeding. ^{(Mayo Clinic 2022, Kearney 2018, Protocolo Barcelona 2018, Greutmann 2015)}

Patients with functional class IV of the New York Heart Association (NYHA) functional classification probably should not or cannot breastfeed. A consensual breastfeeding plan must be established for patients with WHO risk levels III and IV who require a stay in intensive care after delivery.

Dosage has to be adjusted and cardiovascular drugs properly chosen.^{(Kearney 2018)}

Use low dosing of diuretic drugs because the mammary gland acts as a excretory organ of about 1 liter of fluid every day.

It is also necessary to take into account the higher caloric expenditure involved in breastfeeding (1 liter of breast milk is equivalent to about 700 calories).

Given the strong evidence that exists on the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, individually advising each mother that wishes to continue with breastfeeding. ^{(Koren 2013)}

See below the information of these related products:

Digoxin (Safe substance and/or breastfeeding is the best option.)
Dobutamine Hydrochloride (Safe substance and/or breastfeeding is the best option.)
Enalapril (Safe substance and/or breastfeeding is the best option.)
Hydralazine Hydrochloride (Safe substance and/or breastfeeding is the best option.)
Losartan Potassium (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
Metoprolol (Safe substance and/or breastfeeding is the best option.)
Norepinephrine (Safe substance and/or breastfeeding is the best option.)
Spironolactone (Safe substance and/or breastfeeding is the best option.)

See below the information of these related groups:

Safe, best option.

Compatible

More information

Likely Compatibility

More information

Limited compatibility

More information

Incompatible

More information

Safe, best option.

Compatible

More information

Likely Compatibility

More information

Limited compatibility

More information

Incompatible

More information

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Maternal Cardiopathy belongs to this group or family:

NoATC MA1: Maternal Disease, illness, problem or other Mother´s Conditions.

References

List of 6 references

Mayo Clinic. Enfermedades cardíacas y embarazo. Infórmate sobre los riesgos. None 2022 Full text (link to original source) Full text (in our servers)
Mayo Clinic. Heart conditions and pregnancy: Know the risks. None 2022 Abstract Full text (link to original source) Full text (in our servers)
Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)
Protocolo de Barcelona CARDIOPATÍA MATERNA Y GESTACIÓN. Hospital Clínic-Hospital Sant Joan de Déu-Universitat de Barcelona Protocolo 2018 Full text (in our servers)
Greutmann M, Pieper PG. Pregnancy in women with congenital heart disease. Eur Heart J. 2015 Oct 1;36(37):2491-9. Abstract
Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013 Mar;35(3):263-278. Abstract Full text (link to original source) Full text (in our servers)

Maternal Cardiopathy

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Other names

Group

References

Total visits

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?